Blue Owl Capital Holdings’s Eledon Pharmaceuticals ELDN Stock Holding History

Blue Owl Capital Holdings’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.23M	Sell	566,509 -853,403	-60%	-$3.1M	0.34%	31
2026 Q1	$4.37M	Sell	1,419,912 -510,000	-26%	-$1.2M	1.18%	22
2025 Q4	$2.91M	Buy	1,929,912 +950,000	+97%	+$2.26M	0.9%	31
2025 Q3	$2.54M	Sell	979,912 -350,000	-26%	-$1.02M	0.79%	31
2025 Q2	$3.6M	Sell	1,329,912 -490,000	-27%	-$1.47M	1.16%	23
2025 Q1	$6.17M	Sell	1,819,912 -140,000	-7%	-$576K	1.99%	13
2024 Q4	$8.07M	Buy	+1,959,912	New	+$7.73M	1.86%	14

Other funds holding ELDN

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Blue Owl Capital Holdings's ELDN Position: Q2 2026 in Review

Blue Owl Capital Holdings reduced its Eledon Pharmaceuticals (ELDN) stake by 60% in Q2 2026, selling an estimated $3.1M and leaving 566,509 shares worth $2.23M. The position accounts for 0.34% of the portfolio, ranked #31.

Blue Owl Capital Holdings first reported a position in ELDN in Q4 2024 and has held it in 7 quarters since. The position peaked at $8.07M in Q4 2024. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

Blue Owl Capital Holdings held 566,509 shares of Eledon Pharmaceuticals worth $2.23M as of Q2 2026.
Blue Owl Capital Holdings sold 853,403 Eledon Pharmaceuticals shares in Q2 2026, an estimated $3.1M.
Eledon Pharmaceuticals made up 0.34% of Blue Owl Capital Holdings's portfolio in Q2 2026, its #31 holding.
Blue Owl Capital Holdings first reported a position in Eledon Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Blue Owl Capital Holdings's Eledon Pharmaceuticals position peaked at $8.07M in Q4 2024.
161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q2 2026, filed 11 Aug 2026.